{
}
Sanofi is investing 300 million euros for a 16% stake in a new joint venture with Orano Med to develop radiopharmaceuticals targeting rare cancers, particularly using the radioisotope lead-212. This partnership aims to leverage expertise in biopharma and nuclear technology to advance cancer treatment. The joint venture is valued at 1.9 billion euros, following Sanofi's recent licensing of an experimental drug for neuroendocrine tumors.
GSK is suing Moderna for allegedly infringing on seven patents related to mRNA vaccine technology, which were developed by a team led by Christian Mandl during his time at Novartis. GSK claims that Moderna's success in rapidly developing its COVID-19 vaccine relied on these patented methods. The lawsuit seeks unspecified damages and reimbursement for legal costs.
The Swiss stock market experienced a decline mid-week, with the SMI index falling 0.21% to 12,193.07 points amid investor caution ahead of the European Central Bank's interest rate decision. Major losses were seen in luxury goods and technology sectors, particularly for Swatch Group and Richemont, following disappointing figures from LVMH. In contrast, stocks like Autoneum and Julius Baer showed gains, while Tecan plummeted 15% due to a forecast cut.
Sanofi is in negotiations with private equity firm Clayton Dubilier & Rice to sell a 50% controlling stake in its consumer health business, Opella, potentially valued at around €15 billion ($16.4 billion). This sale would allow Sanofi to focus more on its biopharmaceutical operations, which generated over €18 billion in sales in the first half of the year. Opella, known for products like Allegra and Icy Hot, operates in 100 countries and employs over 11,000 people.
Purespring Therapeutics has secured $105 million in Series B funding to advance its gene therapies for kidney diseases, particularly targeting IgA nephropathy (IgAN). The funding, led by Sofinnova Partners, will support a Phase 1/2 study of its lead candidate, utilizing adeno-associated viruses to deliver treatments aimed at the podocytes, which are linked to many renal diseases. The company plans to present its IgAN data at the upcoming American Society of Nephrology’s Kidney Week meeting.
David Baker, Demis Hassabis, and John Jumper have won the Nobel Prize in Chemistry for their groundbreaking work in computational protein design and structure prediction, significantly advancing drug design capabilities. Alnylam Pharmaceuticals seeks FDA approval for vutrisiran to treat a severe form of transthyretin amyloidosis, while Johnson & Johnson halts a bladder cancer trial for TAR-200. AstraZeneca invests in a preclinical cholesterol-lowering drug, and Astellas acquires rights to an experimental gene therapy for frontotemporal dementia.
Rising healthcare costs are straining patients, payers, and providers, limiting access to care and pressuring the pharmaceutical industry to maintain lower prices. The global pharmaceuticals and healthcare market is projected to grow from $1,245.88 billion in 2021 to $1,924.24 billion by 2032, driven by technological advances and demographic changes. However, regulatory barriers and increasing costs pose significant challenges to market growth.
The Swiss stock market opened lower on Thursday, influenced by a slowdown in consumer price inflation, which rose by 0.8% year-on-year in September. The leading SMI index fell by 0.20%, with 25 of the 30 major stocks declining, while Sandoz, Novartis, and Givaudan were among the few gainers. Analysts anticipate a potential rate cut by the Swiss National Bank in December 2024 due to declining inflation forecasts.
The German M&A market is expected to see a significant recovery in 2025, with a projected 20% increase in transactions compared to the previous year, driven by strategic acquisitions and private equity pressures. Cross-border deals will remain high, particularly with U.S. buyers, while sectors like software, AI, and renewable energy are poised for above-average activity. ESG considerations are becoming crucial in M&A decisions, influencing corporate strategies across various industries.
Legal & General Investment Management offers two significant ETFs, L&G Healthcare Breakthrough and L&G Pharma Breakthrough, targeting growth in the healthcare and pharmaceutical sectors. These medium-high risk products can enhance diversified portfolios, especially in light of ongoing interest in medical research post-Covid-19. The iShares Healthcare Innovation UCITS ETF stands out on the Italian stock exchange, reflecting strong performance and a focus on healthcare innovation.
Novartis AG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Sanofi invests 300 million euros in joint venture for radiopharmaceuticals
Euro
Eli Lilly and Company
Orano Group
Bristol-Myers Squibb Company
Novartis AG
AstraZeneca PLC
Bayer AG
Sanofi
FRA
USA
Paul Hudson
Bayer
AstraZeneca
Eli Lilly
Novartis
Show more
13:20 17.10.2024
gsk sues moderna for alleged infringement of mRNA vaccine patents
United States Dollar
Pfizer Inc.
BioNTech SE
Novartis AG
Glaxosmithkline Export Ltd.
Moderna, Inc.
USA
DEU
Christian Mandl
Andrew Geall
Show more
12:59 16.10.2024
Swiss stock market declines as luxury and tech stocks face pressure
18:05 14.10.2024
sanofi in talks to sell consumer health business to private equity firm
Euro
United States Dollar
Clayton, Dubilier & Rice LLC
McKesson Corporation
Glaxosmithkline Export Ltd.
Pfizer Inc.
Merck & Co., Inc.
Novartis AG
Sanofi
Johnson & Johnson
FRA
USA
François Roger
Merck & Co.
Show more
13:47 11.10.2024
Purespring Therapeutics secures 105 million for kidney gene therapy development
14:09 09.10.2024
nobel prize awarded for protein design and drug developments advance
United States Dollar
Eli Lilly and Company
AviadoBio
Alnylam Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Amgen Inc.
Astellas Pharma Inc.
Pfizer Inc.
BridgeBio Pharma, Inc.
Novartis AG
AstraZeneca PLC
Johnson & Johnson
USA
SWE
JPN
BRA
HKG
John Jumper
David Baker
Jonathan Gardner
Demis Hassabis
Jim Wilson
Show more
13:00 09.10.2024
global pharmaceutical and healthcare market projected to reach 1924 billion by 2032
United States Dollar
Hoffmann-La Roche AG
Johnson & Johnson
Novartis AG
Merck & Co., Inc.
AbbVie Inc.
CAN
FRA
GBR
USA
ISR
JPN
DNK
DEU
Merck & Co
Roche
Johnson & Johnson
AbbVie
Novartis
Show more
09:00 07.10.2024
swiss stock market opens lower amid declining inflation figures
Euro
Swiss Franc
Australian Dollar
Malaysian Ringgit
United States Dollar
Kühne + Nagel Ltd.
Nestlé S.A.
Zurich Insurance Group AG
Givaudan SA
Novartis AG
MYS
FRA
CHE
AUS
USA
John Plassard
Brian Mandt
Jurus Arthur
Airties
Britt Hendriksen
Show more
09:00 03.10.2024
german mergers and acquisitions poised for recovery amid economic challenges
Euro
Novartis AG
Evonik IP GmbH
Covestro AG
Novo Nordisk A/S
ARE
SAU
DEU
GBR
USA
FRA
Michael R. Drill
Novo Nordisk
Show more
09:00 01.10.2024
investing in healthcare and pharmaceutical etfs for long term growth opportunities
AstraZeneca PLC
Novartis AG
Sanofi
CHE
USA
GBR
BlackRock
Legal & General Investment Management
Show more
09:00 01.10.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
CEO Changes
Central Bank Actions
GDP Growth & Recession Forecasts
Global Trade Developments
Financial Scams and Security
Industry Mergers & Acquisitions
Inflation and Monetary Impact
Market Analysis and Predictions
Government Policies
Government Economic Policies
Supply Chain Management
Startups & Entrepreneurship
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Bank of America Corporation
Barclays PLC
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Microsoft Corporation
Credit Suisse Strategic Income I
NVIDIA Corporation
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
End Federal Reserve USD
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Australian Dollar
Canadian Dollar
United Arab Emirates Dirham
Indonesian Rupiah
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Hong Kong Dollar
Mexican Peso
Malaysian Ringgit
Vietnamese Đồng
People: